Drug screening reveals pralatrexate could be repurposed to treat COVID-19
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
List view / Grid view
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers have been tracking SARS-CoV-2 by sequencing the genomes of virus samples collected from diagnostic testing. They hope that using next-generation sequencing (NGS) on SARS-CoV-2 will help to accurately diagnose the novel coronavirus, identify mutations and track its history. This article explores the findings of their latest study and what…
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.